Key Points

• Laborate Pharmaceuticals secures EU-GMP certification for its Laborate Pharmaceuticals India Ltd, 111, Paonta Sahib ( H.P.) facility

• Certification enables exports to European Union and other regulated markets

• Company in discussions with Europe and UK for co-development and commercial supply

• Facility equipped for manufacturing Oral Solid Dosage form (Tablet & Capsule) dosage forms in line with global standards

• Projected to increase international revenue by US $ 100 Million  over the next 5 years

• Reinforces Laborate’s commitment to global quality, compliance, and expansion
  
  

New Delhi, 5th August 2025 – Laborate Pharmaceuticals, one of India’s prominent pharmaceutical manufacturing and exporting companies, recently announced that its manufacturing site in  Laborate Pharmaceuticals India Ltd, 111, Paonta Sahib, ( H.P.) has been granted the EU-GMP (European Union – Good Manufacturing Practice) certification from the relevant European regulatory agency.

The certification confirms compliance with the high standards set by the EU for pharmaceutical manufacturers and provides Laborate Pharmaceuticals with new opportunities to export and ship its products to the European Union and other regulated markets. The facility is built for Oral Solid Dosage Form, including Tablets & Capsules, and is fitted with state-of-the-art systems and processes to ensure consistent quality and regulatory compliance.

“This EU-GMP certification provides a clear pathway to our focus on world-class standards of quality and manufacturing to take an unprecedented step to be recognised as the EU-GMP accredited pharmaceutical organisation,” said Parag Bhatia, Director,  Laborate Pharmaceuticals. “The certification confirms our capability to supply and export quality, safe and effective medicines to millions of people around the world.”

Laborate is currently negotiating advanced discussions with clients in Europe  and UK for the co-development and supply of finished formulation products targeted to treat various therapeutic diseases. These agreements will play a key role in Laborate’s international strategy, pipeline expansion over the next 5 years.

The EU-GMP-certified facility, covering 157,500  square feet, has dedicated areas for 53000. The facility was audited and certified after a detailed investigation of its processes, systems, documentation, and quality management systems.

In fact, the facility certification provides a path to filing regulatory dossiers for multiple products in the EU market. The company intends to file 20 dossiers over the next 5 months to obtain approvals in Europe, UK, Australia and South Africa. The company is also exploring additional certifications via authorities such as GCC, EAEU to enhance its presence in regulated markets.

“We are focused on establishing longer-term partnerships with global companies that value reliable and scalable manufacturing at a cost-effective and compliant basis,” said Parag Bhatia, Director,  Laborate Pharmaceuticals.